Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies. Clayton, A. H, Croft, H. A, Horrigan, J. P, Wightman, D. S, Krishen, A., Richard, N. E, & Modell, J. G The Journal of clinical psychiatry, 67(5):736--746, May, 2006. ![Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies [link]](https://bibbase.org/img/filetypes/link.svg "link")
Paper abstract bibtex OBJECTIVE: To compare the effects on sexual functioning and the antidepressant efficacy of once-daily bupropion extended release (XL) and escitalopram in adults with major depressive disorder (MDD). METHOD: Adult outpatients with moderate to severe DSM-IV-defined MDD and normal sexual functioning were randomly assigned to receive bupropion XL (300-450 mg/day; N = 276), escitalopram (10-20 mg/day; N = 281), or placebo (N = 273) for up to 8 weeks in 2 identically designed, randomized, double-blind, parallel-group studies (study 1 conducted from February 6, 2003, to June 10, 2004; study 2 conducted from January 21, 2003, to June 15, 2004). Data were analyzed prospectively for each study individually, and pooled data were analyzed retrospectively. RESULTS: In both the individual studies and the pooled dataset, the incidence of orgasm dysfunction at week 8 (primary endpoint) and the incidence of worsened sexual functioning at the end of the treatment period were statistically significantly lower with bupropion XL than with escitalopram (p or = .067), and statistically significantly higher with escitalopram than with placebo (p \textless or = .001). The percentages of patients with orgasm dysfunction at week 8 in study 1, study 2, and the pooled dataset, respectively, were 13%, 16%, and 15% with bupropion XL; 32%, 29%, and 30% with escitalopram; and 11%, 8%, and 9% with placebo. The respective percentages of patients with worsened sexual functioning at the end of the treatment period were 18%, 22%, and 20% with bupropion XL; 37%, 34%, and 36% with escitalopram; and 14%, 16%, and 15% with placebo. Mean changes in Changes in Sexual Functioning Questionnaire scores for all domains at week 8 were statistically significantly worse for escitalopram compared with bupropion XL (p \textless or = .05). Separation from placebo could not be established at a statistical .05 level for bupropion on 17-item Hamilton Rating Scale for Depression (HAM-D-17) total score. However, escitalopram showed statistical superiority to placebo on HAM-D-17 total score in one of the 2 studies and in the pooled data. Bupropion XL did not statistically differ from escitalopram with respect to mean change in HAM-D-17 total score, HAM-D-17 response or remission rates, percentage of patients much or very much improved on Clinical Global Impressions-Improvement scale scores, or mean changes in the Hospital Anxiety and Depression (HAD) scale total score or Clinical Global Impressions-Severity of Illness scale score at week 8. CONCLUSIONS: Bupropion XL had a sexual tolerability profile significantly better than that of escitalopram with similar HAM-D-17 remission rates and HAD total scores in patients with MDD.
@article{clayton_bupropion_2006,
title = {Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies},
volume = {67},
issn = {0160-6689},
url = {http://www.ncbi.nlm.nih.gov/pubmed/16841623},
abstract = {OBJECTIVE: To compare the effects on sexual functioning and the antidepressant efficacy of once-daily bupropion extended release (XL) and escitalopram in adults with major depressive disorder (MDD). METHOD: Adult outpatients with moderate to severe DSM-IV-defined MDD and normal sexual functioning were randomly assigned to receive bupropion XL (300-450 mg/day; N = 276), escitalopram (10-20 mg/day; N = 281), or placebo (N = 273) for up to 8 weeks in 2 identically designed, randomized, double-blind, parallel-group studies (study 1 conducted from February 6, 2003, to June 10, 2004; study 2 conducted from January 21, 2003, to June 15, 2004). Data were analyzed prospectively for each study individually, and pooled data were analyzed retrospectively. RESULTS: In both the individual studies and the pooled dataset, the incidence of orgasm dysfunction at week 8 (primary endpoint) and the incidence of worsened sexual functioning at the end of the treatment period were statistically significantly lower with bupropion XL than with escitalopram (p or = .067), and statistically significantly higher with escitalopram than with placebo (p {\textless} or = .001). The percentages of patients with orgasm dysfunction at week 8 in study 1, study 2, and the pooled dataset, respectively, were 13\%, 16\%, and 15\% with bupropion XL; 32\%, 29\%, and 30\% with escitalopram; and 11\%, 8\%, and 9\% with placebo. The respective percentages of patients with worsened sexual functioning at the end of the treatment period were 18\%, 22\%, and 20\% with bupropion XL; 37\%, 34\%, and 36\% with escitalopram; and 14\%, 16\%, and 15\% with placebo. Mean changes in Changes in Sexual Functioning Questionnaire scores for all domains at week 8 were statistically significantly worse for escitalopram compared with bupropion XL (p {\textless} or = .05). Separation from placebo could not be established at a statistical .05 level for bupropion on 17-item Hamilton Rating Scale for Depression (HAM-D-17) total score. However, escitalopram showed statistical superiority to placebo on HAM-D-17 total score in one of the 2 studies and in the pooled data. Bupropion XL did not statistically differ from escitalopram with respect to mean change in HAM-D-17 total score, HAM-D-17 response or remission rates, percentage of patients much or very much improved on Clinical Global Impressions-Improvement scale scores, or mean changes in the Hospital Anxiety and Depression (HAD) scale total score or Clinical Global Impressions-Severity of Illness scale score at week 8. CONCLUSIONS: Bupropion XL had a sexual tolerability profile significantly better than that of escitalopram with similar HAM-D-17 remission rates and HAD total scores in patients with MDD.},
language = {en},
number = {5},
journal = {The Journal of clinical psychiatry},
author = {Clayton, Anita H and Croft, Harry A and Horrigan, Joseph P and Wightman, Donna S and Krishen, Alok and Richard, Nathalie E and Modell, Jack G},
month = may,
year = {2006},
pmid = {16841623},
keywords = {Mental Health/Science: Pharmacology},
pages = {736--746}
}
Downloads: 0
{"_id":"4tzgrW5oNnaMrbk22","bibbaseid":"clayton-croft-horrigan-wightman-krishen-richard-modell-bupropionextendedreleasecomparedwithescitaloprameffectsonsexualfunctioningandantidepressantefficacyin2randomizeddoubleblindplacebocontrolledstudies-2006","downloads":0,"creationDate":"2018-03-15T15:56:58.764Z","title":"Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies","author_short":["Clayton, A. H","Croft, H. A","Horrigan, J. P","Wightman, D. S","Krishen, A.","Richard, N. E","Modell, J. G"],"year":2006,"bibtype":"article","biburl":"http://bibbase.org/zotero/davidlloyd3","bibdata":{"bibtype":"article","type":"article","title":"Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies","volume":"67","issn":"0160-6689","url":"http://www.ncbi.nlm.nih.gov/pubmed/16841623","abstract":"OBJECTIVE: To compare the effects on sexual functioning and the antidepressant efficacy of once-daily bupropion extended release (XL) and escitalopram in adults with major depressive disorder (MDD). METHOD: Adult outpatients with moderate to severe DSM-IV-defined MDD and normal sexual functioning were randomly assigned to receive bupropion XL (300-450 mg/day; N = 276), escitalopram (10-20 mg/day; N = 281), or placebo (N = 273) for up to 8 weeks in 2 identically designed, randomized, double-blind, parallel-group studies (study 1 conducted from February 6, 2003, to June 10, 2004; study 2 conducted from January 21, 2003, to June 15, 2004). Data were analyzed prospectively for each study individually, and pooled data were analyzed retrospectively. RESULTS: In both the individual studies and the pooled dataset, the incidence of orgasm dysfunction at week 8 (primary endpoint) and the incidence of worsened sexual functioning at the end of the treatment period were statistically significantly lower with bupropion XL than with escitalopram (p or = .067), and statistically significantly higher with escitalopram than with placebo (p \\textless or = .001). The percentages of patients with orgasm dysfunction at week 8 in study 1, study 2, and the pooled dataset, respectively, were 13%, 16%, and 15% with bupropion XL; 32%, 29%, and 30% with escitalopram; and 11%, 8%, and 9% with placebo. The respective percentages of patients with worsened sexual functioning at the end of the treatment period were 18%, 22%, and 20% with bupropion XL; 37%, 34%, and 36% with escitalopram; and 14%, 16%, and 15% with placebo. Mean changes in Changes in Sexual Functioning Questionnaire scores for all domains at week 8 were statistically significantly worse for escitalopram compared with bupropion XL (p \\textless or = .05). Separation from placebo could not be established at a statistical .05 level for bupropion on 17-item Hamilton Rating Scale for Depression (HAM-D-17) total score. However, escitalopram showed statistical superiority to placebo on HAM-D-17 total score in one of the 2 studies and in the pooled data. Bupropion XL did not statistically differ from escitalopram with respect to mean change in HAM-D-17 total score, HAM-D-17 response or remission rates, percentage of patients much or very much improved on Clinical Global Impressions-Improvement scale scores, or mean changes in the Hospital Anxiety and Depression (HAD) scale total score or Clinical Global Impressions-Severity of Illness scale score at week 8. CONCLUSIONS: Bupropion XL had a sexual tolerability profile significantly better than that of escitalopram with similar HAM-D-17 remission rates and HAD total scores in patients with MDD.","language":"en","number":"5","journal":"The Journal of clinical psychiatry","author":[{"propositions":[],"lastnames":["Clayton"],"firstnames":["Anita","H"],"suffixes":[]},{"propositions":[],"lastnames":["Croft"],"firstnames":["Harry","A"],"suffixes":[]},{"propositions":[],"lastnames":["Horrigan"],"firstnames":["Joseph","P"],"suffixes":[]},{"propositions":[],"lastnames":["Wightman"],"firstnames":["Donna","S"],"suffixes":[]},{"propositions":[],"lastnames":["Krishen"],"firstnames":["Alok"],"suffixes":[]},{"propositions":[],"lastnames":["Richard"],"firstnames":["Nathalie","E"],"suffixes":[]},{"propositions":[],"lastnames":["Modell"],"firstnames":["Jack","G"],"suffixes":[]}],"month":"May","year":"2006","pmid":"16841623","keywords":"Mental Health/Science: Pharmacology","pages":"736--746","bibtex":"@article{clayton_bupropion_2006,\n\ttitle = {Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies},\n\tvolume = {67},\n\tissn = {0160-6689},\n\turl = {http://www.ncbi.nlm.nih.gov/pubmed/16841623},\n\tabstract = {OBJECTIVE: To compare the effects on sexual functioning and the antidepressant efficacy of once-daily bupropion extended release (XL) and escitalopram in adults with major depressive disorder (MDD). METHOD: Adult outpatients with moderate to severe DSM-IV-defined MDD and normal sexual functioning were randomly assigned to receive bupropion XL (300-450 mg/day; N = 276), escitalopram (10-20 mg/day; N = 281), or placebo (N = 273) for up to 8 weeks in 2 identically designed, randomized, double-blind, parallel-group studies (study 1 conducted from February 6, 2003, to June 10, 2004; study 2 conducted from January 21, 2003, to June 15, 2004). Data were analyzed prospectively for each study individually, and pooled data were analyzed retrospectively. RESULTS: In both the individual studies and the pooled dataset, the incidence of orgasm dysfunction at week 8 (primary endpoint) and the incidence of worsened sexual functioning at the end of the treatment period were statistically significantly lower with bupropion XL than with escitalopram (p or = .067), and statistically significantly higher with escitalopram than with placebo (p {\\textless} or = .001). The percentages of patients with orgasm dysfunction at week 8 in study 1, study 2, and the pooled dataset, respectively, were 13\\%, 16\\%, and 15\\% with bupropion XL; 32\\%, 29\\%, and 30\\% with escitalopram; and 11\\%, 8\\%, and 9\\% with placebo. The respective percentages of patients with worsened sexual functioning at the end of the treatment period were 18\\%, 22\\%, and 20\\% with bupropion XL; 37\\%, 34\\%, and 36\\% with escitalopram; and 14\\%, 16\\%, and 15\\% with placebo. Mean changes in Changes in Sexual Functioning Questionnaire scores for all domains at week 8 were statistically significantly worse for escitalopram compared with bupropion XL (p {\\textless} or = .05). Separation from placebo could not be established at a statistical .05 level for bupropion on 17-item Hamilton Rating Scale for Depression (HAM-D-17) total score. However, escitalopram showed statistical superiority to placebo on HAM-D-17 total score in one of the 2 studies and in the pooled data. Bupropion XL did not statistically differ from escitalopram with respect to mean change in HAM-D-17 total score, HAM-D-17 response or remission rates, percentage of patients much or very much improved on Clinical Global Impressions-Improvement scale scores, or mean changes in the Hospital Anxiety and Depression (HAD) scale total score or Clinical Global Impressions-Severity of Illness scale score at week 8. CONCLUSIONS: Bupropion XL had a sexual tolerability profile significantly better than that of escitalopram with similar HAM-D-17 remission rates and HAD total scores in patients with MDD.},\n\tlanguage = {en},\n\tnumber = {5},\n\tjournal = {The Journal of clinical psychiatry},\n\tauthor = {Clayton, Anita H and Croft, Harry A and Horrigan, Joseph P and Wightman, Donna S and Krishen, Alok and Richard, Nathalie E and Modell, Jack G},\n\tmonth = may,\n\tyear = {2006},\n\tpmid = {16841623},\n\tkeywords = {Mental Health/Science: Pharmacology},\n\tpages = {736--746}\n}\n\n","author_short":["Clayton, A. H","Croft, H. A","Horrigan, J. P","Wightman, D. S","Krishen, A.","Richard, N. E","Modell, J. G"],"key":"clayton_bupropion_2006","id":"clayton_bupropion_2006","bibbaseid":"clayton-croft-horrigan-wightman-krishen-richard-modell-bupropionextendedreleasecomparedwithescitaloprameffectsonsexualfunctioningandantidepressantefficacyin2randomizeddoubleblindplacebocontrolledstudies-2006","role":"author","urls":{"Paper":"http://www.ncbi.nlm.nih.gov/pubmed/16841623"},"keyword":["Mental Health/Science: Pharmacology"],"downloads":0},"search_terms":["bupropion","extended","release","compared","escitalopram","effects","sexual","functioning","antidepressant","efficacy","randomized","double","blind","placebo","controlled","studies","clayton","croft","horrigan","wightman","krishen","richard","modell"],"keywords":["mental health/science: pharmacology"],"authorIDs":[],"dataSources":["kRLSZGSDAgwZPh2tM"]}